CClinicalTrials.gg
RecruitingNCT07628140Updated Aug 27, 2026

Kulindana: Community-friendly Delivery and Monitoring of TPT to Improve Uptake and Reduce TB Transmission

An interventional study of Differentiated service delivery (DSD) of TB preventive therapy (TPT) in Tuberculosis Prevention and HIV, sponsored by University of Washington. Recruiting at 1 site in Kenya. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by University of Washington · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Sex
All
01

Study summary

The goal of this clinical trial is to learn if differentiated service delivery (DSD) of TB preventive therapy (TPT) improves uptake and completion of TPT in two populations: household contacts (HHC) of index TB patients and people living with HIV (PWH). The main questions it aims to answer are:

  • Is community-based and multi-month dispensing of short-course TPT with minimal clinic and laboratory monitoring associated with higher rates of initiation and completion of TPT, compared to standard of care, in both HHC and PWH?
  • Does community-based and DSD TPT reduce household and community TB transmission?

Researchers will compare DSD TPT delivery to standard of care (SoC) to see if DSD TPT delivery has an effect on TPT uptake and completion.

Participants will:

  • Be assessed for TPT eligibility through either DSD TPT service delivery of SoC including differentiated TB screening procedures.
  • If eligible, receive DSD TPT service delivery or SoC TPT service delivery.
  • Over 12 weeks receive either DSD or SoC TPT adherence assessment and follow-up.
  • Have TPT completion assessed at 12 weeks following enrolment.
  • A subset of participants will be assess for TB incidence at 9 months following enrolment.
Read the detailed description

The investigators will conduct a two-arm, non-blinded, randomized controlled trial (RCT) comparing differentiated TPT delivery to standard of care (SOC) clinic-based TPT. The central hypothesis is that decentralized, differentiated-service delivery approaches to TPT will improve TPT uptake and completion in Kenya. This study will be conducted in seven HIV clinics in Kisumu County, a high HIV/TB burden region in western Kenya. This study has two populations:

(A) Household contacts (HHC) of Index TB patients (Index patients: any age, diagnosed with pulmonary TB (or any TB if \<18 years), who live with at least one other person not currently taking TB treatment). The TB index patients and household contacts include children.

(B) People living with HIV (PWH), aged 15+ who are eligible for TPT per Kenyan guidelines.

The primary outcome, 3 months after enrollment, is completion of a course of TPT, defined as taking 11 weeks of TPT within 16 weeks.

02

Conditions studied

  • Tuberculosis Prevention
  • HIV

Browse trials for

Keywords

  • tuberculosis
  • household contact
  • TB preventive therapy
  • 3HP
  • HIV
  • contact investigation
  • multi-month dispensing
  • differentiated service delivery
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Household contacts (HHC) are eligible for enrolment if the participant shares a residential dwelling with an index TB patient and can provide informed consent (or parental consent, with assent if appropriate).
  • People living with HIV (PWH) are eligible for enrolment if the participant is an adult aged 15 and over, is eligible for TPT according to Kenyan National Guidelines, and can provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • HHC will be excluded if the participant plans on permanently relocating from the area within the next three months, is not willing to receive TPT screening and initiation at home, or is enrolled in any other investigational/interventional HIV or TB study.
  • PWH will be excluded if the participant plans on permanently relocating from the area within the next three months, has contraindications for TPT according to the Kenyan National Guidelines, or is enrolled in any other investigational/interventional HIV or TB study.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Differentiated service delivery (DSD) of TPT

    In the household contact (HHC) population DSD TPT will be delivered at home in a single dispense of a full course of TPT; in the people living with HIV (PWH) population DSD TPT will be delivered at the clinic in a single dispense of a full course of TPT.

    Other: Differentiated service delivery (DSD) of TB preventive therapy (TPT)

  • No intervention
    Clinic-based standard of care

    Both the household contact (HHC) population and the people living with HIV (PWH) population have TPT dispensed at the clinic according to standard practice, typically one month at a time.

Interventions

  • OtherDifferentiated service delivery (DSD) of TB preventive therapy (TPT)

    TPT is normally provided at clinics with monthly visits for refills, but the full course of TPT can also be provided all at once through differentiated service delivery (DSD) of TPT. By doing the Kulindana study, the investigators hope to learn which way of delivering TPT to participants (through usual clinic practice, or all at once) is best for helping participants finish a full course of TPT.

05

What researchers measure

Primary outcomes

  1. TB preventive therapy completion

    Proportion of participants completing 11 out of 12 weeks of TPT within 16 weeks

    Time frame: 16 weeks

Secondary outcomes

  1. IGRA conversion

    Proportion of child household contacts (age \<15 years) who convert their IGRA result from negative to positive.

    Time frame: 9 months

06

Study locations

1 of 1 sites recruiting
  • Centre for Family Health Research and Development (CEFERD) located at Jaramogi Oginga Odinga Teaching and Referral Hospital
    Kisumu, Kenya
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — A limited de-identified clinical dataset will be deposited in a public repository.

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07628140
Lead sponsor
University of Washington
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Adrienne E Shapiro (Assistant Professor in the Departments of Global Health and Medicine (Infectious Diseases), University of Washington) — Principal investigator
First posted
Jun 4, 2026
Start date
Jul 14, 2026
Primary completion
Jul 2030 (estimated)
Completion
Jul 2031 (estimated)
Last update
Aug 27, 2026

Study contacts

Gillian O'Bryan
Contact
gilliano@uw.edu
240-444-0098
Adrienne Shapiro, MD, PhD
Contact
aeshapir@uw.edu
Adrienne Shapiro, MD, PhD
principal investigator · University of Washington

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion